Alector, Inc. (NASDAQ:ALEC) Given Consensus Recommendation of “Hold” by Brokerages

Alector, Inc. (NASDAQ:ALEC) has been assigned an average recommendation of “Hold” from the eight analysts that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $3.6250.

Several research analysts have weighed in on ALEC shares. Cantor Fitzgerald upgraded shares of Alector from a “neutral” rating to an “overweight” rating in a report on Wednesday, April 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Alector in a report on Monday, May 4th. Wall Street Zen upgraded shares of Alector from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Morgan Stanley restated an “underweight” rating and set a $2.00 price objective on shares of Alector in a report on Monday, May 4th. Finally, BTIG Research upgraded shares of Alector from a “neutral” rating to a “buy” rating and set a $6.00 price objective on the stock in a report on Tuesday, March 10th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Bank of America Corp DE increased its holdings in Alector by 1.8% during the second quarter. Bank of America Corp DE now owns 343,909 shares of the company’s stock worth $481,000 after buying an additional 5,927 shares during the last quarter. Mackenzie Financial Corp increased its holdings in Alector by 3.4% during the third quarter. Mackenzie Financial Corp now owns 283,712 shares of the company’s stock worth $840,000 after buying an additional 9,270 shares during the last quarter. Lexington Partners L.P. purchased a new stake in Alector during the third quarter worth about $30,000. Hershey Trust Co. increased its holdings in Alector by 100.0% during the fourth quarter. Hershey Trust Co. now owns 20,572 shares of the company’s stock worth $32,000 after buying an additional 10,286 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in Alector by 4.7% during the first quarter. Jane Street Group LLC now owns 256,551 shares of the company’s stock worth $316,000 after buying an additional 11,618 shares during the last quarter. Institutional investors and hedge funds own 85.83% of the company’s stock.

Alector Stock Up 0.5%

Shares of NASDAQ ALEC opened at $2.16 on Friday. The firm has a market cap of $239.82 million, a PE ratio of -1.82 and a beta of 0.64. Alector has a 12-month low of $1.09 and a 12-month high of $3.40. The company’s fifty day simple moving average is $2.29 and its 200 day simple moving average is $1.92. The company has a quick ratio of 5.25, a current ratio of 5.25 and a debt-to-equity ratio of 0.80.

Alector (NASDAQ:ALEC) last issued its earnings results on Thursday, May 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. Alector had a negative net margin of 680.83% and a negative return on equity of 295.17%. The business had revenue of $1.05 million for the quarter, compared to analyst estimates of $9.67 million. As a group, sell-side analysts forecast that Alector will post -0.86 earnings per share for the current fiscal year.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.